Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chromium picolinate + biotin is an oral fixed-dose nutritional supplement combination developed and marketed by Nutrition 21 as **Diachrome**. The studied formulation supplied 600 mcg elemental chromium as chromium picolinate plus 2 mg biotin once daily and was evaluated as an adjunct to stable oral antidiabetic therapy in people with poorly controlled type 2 diabetes mellitus. Chromium is proposed to support insulin signaling and glucose transporter trafficking, while biotin is a cofactor for carboxylase enzymes and may influence glucose-metabolism gene regulation. Randomized studies reported improvements in glycemic and selected lipid measures, but the combination is a dietary supplement rather than a conventional approved pharmaceutical antidiabetic medicine. ([europepmc.org](https://europepmc.org/article/MED/17506119))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chromium picolinate + biotin.